Sugi Predict

Sugi Predict / Compounds / SCHEMBL391128

SCHEMBL391128

SCHEMBL391128

[CH2]C[C@H](NC(=O)OC(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ TRPA1 O75762 1/20 0.44
▸ GAA P10253 2/20 0.44
▸ S1PR3 Q99500 1/20 0.43
▸ P2RY2 P41231 1/20 0.42
▸ CACNA1B Q00975 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CTSS P25774 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ CNR1 P21554 3/20 0.40
▸ CNR2 P34972 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20544831 1.00 PPARG (0.46) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL20544755 0.89 P2RY2 (0.45) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL392217 0.89 PPARG (0.46) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL393133 0.87 GAA (0.48) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL14847725 0.87 GAA (0.48) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL27759557 0.85 CTSK (0.54) PPARGPPARAALDH1A1MAPTCTSS
SCHEMBL391263 0.85 P2RY2 (0.47) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL17603813 0.84 P2RY2 (0.46) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL390753 0.84 P2RY2 (0.46) PPARGPPARAALDH1A1MAPTTRPA1
SCHEMBL391918 0.84 KMT2A (0.53) PPARGPPARAALDH1A1MAPTTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
US-9492453-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2016-11-15 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
CN-101861321-B Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2013-02-06 — — CN disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 PPARG 3172/4885PPARA 3942/4885ALDH1A1 4719/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 PPARG 3172/4885PPARA 3942/4885ALDH1A1 4719/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 PPARG 3172/4885PPARA 3942/4885ALDH1A1 4719/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 PPARG 3172/4885PPARA 3942/4885ALDH1A1 4719/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 PPARG 3405/4885PPARA 4173/4885ALDH1A1 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.